Do we need a new levodopa?

Neural Regeneration Research

Volumn 11, Issue 5, 2016, Pages 731-732

  Müller, Thomas ^a  

^a St Joseph Hospital Berlin Tempelhof   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); DOPA DECARBOXYLASE INHIBITOR; HOMOCYSTEINE; LEVODOPA; NEUROTROPHIN;

BLOOD BRAIN BARRIER; BRAIN ATROPHY; CHRONIC INFLAMMATION; COGNITION; DEPLETION; DNA METHYLATION; FREE RADICAL SCAVENGING ASSAY; HUMAN; LOCOMOTION; LUNG INJURY; MORTALITY RATE; NEUROTRANSMISSION; NOTE; OXIDATIVE STRESS; PARKINSON DISEASE; POLYNEUROPATHY;

EID: 84971472359     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.182694     Document Type: Note

References (10)

1. Fahn S (2006) Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl 1-15.
2. Hinz M, Stein A, Cole T (2014) The Parkinson's disease death rate: carbidopa and vitamin B6. Clin Pharmacol 6: 161-169.
3. Müller T (2013) Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease. Expert Rev Neurother 13: 707-718.
4. Müller T, Kuhn W (2009) Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord 24: 929-932.
5. Müller T, Muhlack S (2014) Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients. J Neural Transm 121: 643-648.
6. Müller T, Kohlhepp W (2016) Hypomethylation in Parkinson's disease: An epigenetic drug effect? Mov Disord doi: 10. 1002/mds. 26560.
7. Müller T, Trommer I, Muhlack S, Mueller BK (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease. J Neural Transm 123: 401-406.
8. Przuntek H, Müller T, Riederer P (2004) Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 111: 201-216.
9. Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K (2013) Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12: 747-755.
10. Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, Gonzalez GA, Fernandez E, Murer MG, Gershanik OS (2016) Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease. Neuropharmacology 101: 576-589.